CHMMF (Chimeric Therapeutics) Beginning Cash Position : $1.58 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Beginning Cash Position?

Chimeric Therapeutics's Beginning Cash Position for the quarter that ended in Dec. 2023 was $1.58 Mil.

Chimeric Therapeutics's quarterly Beginning Cash Position declined from Dec. 2022 ($12.40 Mil) to Jun. 2023 ($2.43 Mil) and declined from Jun. 2023 ($2.43 Mil) to Dec. 2023 ($1.58 Mil).

Chimeric Therapeutics's annual Beginning Cash Position declined from Jun. 2022 ($15.75 Mil) to Jun. 2023 ($12.34 Mil) and declined from Jun. 2023 ($12.34 Mil) to Jun. 2024 ($1.57 Mil).

Chimeric Therapeutics Beginning Cash Position Historical Data

The historical data trend for Chimeric Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Beginning Cash Position Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Beginning Cash Position

15.75

12.34

1.57

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Beginning Cash Position	Get a 7-Day Free Trial			9.44	12.40	2.43	1.58	2.34

Chimeric Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Chimeric Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (OTCPK:CHMMF) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

CHM:Australia

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics Headlines

From GuruFocus

Chimeric Therapeutics Ltd FNN Investor Event Transcript

By GuruFocus Research • 02-13-2024

Chimeric Therapeutics Ltd Investor Webinar Transcript

By GuruFocus Research • 02-13-2024

Chimeric Therapeutics Ltd at NWR Communications Virtual Conference Transcript

By GuruFocus Research • 02-13-2024